



## Programme Agenda

Time	Program	Speaker/Chair/Moderator
10:50	Welcome Message	HKIORS
<b>Session 1: Practice-changing clinical trials in ASCO 2026</b> <b>Chairpersons: Prof. Matthew Chiu, HK   Prof. XiangHong Peng, Macau</b>		
11:00 - 11:20	Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.	Prof. Peter Schmid, UK
11:20 - 11:40	Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor–positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i).	Prof. Komal Jhaveri, US
11:40 - 12:00	Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro	Prof. Kevin Kalinsky, US
12:00 - 12:20	Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-03 study of participants (pts) with previously untreated metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) vs chemotherapy (chemo).	Prof. Matthew Chiu, HK
12:20 - 12:40	Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.	Prof. Erika Hamilton, US
12:40 - 13:00	A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P).	Prof. Yeon Hee Park, Korea
13:00 - 13:20	Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.	Dr. Johnny Lau, HK
13:20 - 14:20	Lunch break and industry updates	
14:20 - 14:50	<b>Highlight session chaired by Prof. Spring Kong, HK</b> Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.	Dr. Ken Wong, HK
<b>Session 2: Advances in cancer diagnostics: minimally residual disease (MRD) and ctDNA in guiding cancer treatment</b> <b>Chairpersons: Prof. Spring Kong, HK   Dr. Johnny Lau, HK</b>		
14:50 - 15:10	Tumor-naïve multimodal cfDNA MRD assay to predict recurrence in a prospective cohort of patients undergoing curative-intent lung cancer resection.	Prof. Spring Kong, HK
15:10 - 15:30	Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study.	Prof. Mitsuru Yokota, Japan
15:30 - 15:50	Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib + panitumumab efficacy and prognosis in KRAS G12C–mutated colorectal cancer (mCRC): Results from phase 3 CodeBreak 300.	Prof. Filippo Pietrantonio, Italy
15:50 - 16:10	Multi-omics in guiding cancer treatment	Dr. Chen Ching Tso, Taiwan
16:10 - 16:30	Experts sharing and audience discussion: Are we ready to use MRD to guide cancer management yet ?	
16:30	Closing Remarks	HKIORS